In recent years, pharmacotherapy for diabetic retinopathy (DR) has gradually shifted from traditional single‑target anti‑VEGF intervention to multi‑pathway coordinated regulation.Evidence‑based medical data for the bispecific antibody faricimab (Ang‑2/VEGF‑A dual inhibitor) in DR treatment continues to accumulate.Post hoc analyses of the YOSEMITE/RHINE trials revealed that faricimab significantly enhances vascular stability compared with aflibercept, and the injection […]